Do you have advanced non-small cell lung cancer?

Talk with your doctor about the Lung-MAP clinical trial

**USUAL CARE**

If you have non-small cell lung cancer (NSCLC) that is advanced (that may have spread to other parts of your body or has returned after treatment), usual care often involves chemotherapy or immunotherapy. Even when chemotherapy or immunotherapy works, lung cancer often returns. If your lung cancer continues to grow or returns after treatment, you may be eligible to receive different therapies.

**PURPOSE OF THIS TRIAL**

Lung-MAP is a large clinical trial testing new therapies for patients who have advanced-stage NSCLC. There are many changes to a person’s cancer genes that can cause lung cancer cells to grow. Researchers have developed new drugs that might better “target” these genetic changes with fewer treatment side effects. Lung-MAP hopes to learn if these drugs will slow or stop the NSCLC from growing. The first step toward joining Lung-MAP is having your tumor tested for the genetic changes being studied. If your tumor has one or more of these changes, you may be able to enroll in a Lung-MAP drug study targeting one of the genetic changes.

**WHAT IF MY TUMOR DOES NOT HAVE ONE OF THE GENETIC CHANGES**

If your tumor does not match any of the genetic changes being tested in Lung-MAP, you may be able to join a “non-match” study. These “non-match” studies test drugs that may help the immune system fight cancer cells. These studies will be available to patients whose cancer has continued to grow or has returned after receiving immunotherapy and/or chemotherapy. Patients in these studies will be assigned to one of two groups. One group will receive the study drugs, and the other group will receive a current standard of care drug treatment.
Currently, we do not know if the study drugs are better than the current standard of care drug treatment. The Lung-MAP studies may or may not directly benefit you; however, the information obtained from these studies will help researchers learn more about the targeted therapies as cancer treatments for future patients.

- Your doctor may need to take another biopsy of your tumor, which may cause some bleeding, pain, or bruising. You may also develop an infection.
- You may have side effects from the drugs used.
- There may be privacy risks. We have strict rules and procedures in place to protect your identity, but we cannot guarantee that your identity will never become known.

Study sponsors pay for the genetic testing of your tumor tissue and for the study drug. You and your insurance company are responsible for other care costs. Check with your insurance company to find out the costs it will and will not pay. Patients who enroll in Lung-MAP will not be compensated.

You may be in a study until your tumor returns or grows (up to three years). If this happens, you may stop participating in Lung-MAP or, if you are eligible, you may join another Lung-MAP study. You can change your mind about taking part in this study for any reason, at any time.

Whether or not you join a study, your doctor will check your health status every six months for up to three years from the time you are assigned to a study.

Your doctor may ask you to stop the study if it is in your best interest, if new information becomes available, if you do not follow the study rules, or if the study is stopped.